These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36878064)

  • 21. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.
    Yen SC; Chen LC; Huang HL; HuangFu WC; Chen YY; Eight Lin T; Lien ST; Tseng HJ; Sung TY; Hsieh JH; Huang WJ; Pan SL; Hsu KC
    Bioorg Chem; 2022 Apr; 121():105675. PubMed ID: 35182882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.
    Kang JB; Chen L; Leng XJ; Wang JJ; Cheng Y; Wu SH; Ma YY; Yang LJ; Cao YH; Yang X; Tong ZJ; Wu JZ; Wang YB; Zhou H; Liu JC; Ding N; Dai WC; Yu YC; Xue X; Sun SL; Dai XB; Chang L; Wang XL; Li NG; Shi ZH
    Bioorg Med Chem; 2022 Sep; 70():116937. PubMed ID: 35863236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
    Lee JH; Shin JE; Kim W; Jeong P; Kim MJ; Oh SJ; Lee HJ; Park HW; Han SY; Kim YC
    Eur J Med Chem; 2022 Jul; 237():114356. PubMed ID: 35489222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors.
    Li X; Yang T; Hu M; Yang Y; Tang M; Deng D; Liu K; Fu S; Tan Y; Wang H; Chen Y; Zhang C; Guo Y; Peng B; Si W; Yang Z; Chen L
    Bioorg Chem; 2022 Apr; 121():105669. PubMed ID: 35180490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor.
    Lou YJ
    Acta Pharmacol Sin; 2012 Feb; 33(2):212-3. PubMed ID: 22231396
    [No Abstract]   [Full Text] [Related]  

  • 27. Discovery of quinolinone derivatives as potent FLT3 inhibitors.
    Chung HJ; Kamli MR; Lee HJ; Ha JD; Cho SY; Lee J; Kong JY; Han SY
    Biochem Biophys Res Commun; 2014 Mar; 445(3):561-5. PubMed ID: 24530392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
    Goh KC; Novotny-Diermayr V; Hart S; Ong LC; Loh YK; Cheong A; Tan YC; Hu C; Jayaraman R; William AD; Sun ET; Dymock BW; Ong KH; Ethirajulu K; Burrows F; Wood JM
    Leukemia; 2012 Feb; 26(2):236-43. PubMed ID: 21860433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations.
    Wang Z; Lu X; Liu C; Huang F; Lu T; Chen Y; Liu L; Lu S
    Eur J Med Chem; 2024 Mar; 268():116237. PubMed ID: 38387337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer.
    Lin WH; Yeh TK; Jiaang WT; Yen KJ; Chen CH; Huang CT; Yen SC; Hsieh SY; Chou LH; Chen CP; Chiu CH; Kao LC; Chao YS; Chen CT; Hsu JT
    PLoS One; 2014; 9(1):e83160. PubMed ID: 24416160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
    Bavetsias V; Crumpler S; Sun C; Avery S; Atrash B; Faisal A; Moore AS; Kosmopoulou M; Brown N; Sheldrake PW; Bush K; Henley A; Box G; Valenti M; de Haven Brandon A; Raynaud FI; Workman P; Eccles SA; Bayliss R; Linardopoulos S; Blagg J
    J Med Chem; 2012 Oct; 55(20):8721-34. PubMed ID: 23043539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
    Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
    Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
    Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
    Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.
    Yen SC; Wu YW; Huang CC; Chao MW; Tu HJ; Chen LC; Lin TE; Sung TY; Tseng HJ; Chu JC; Huang WJ; Yang CR; HuangFu WC; Pan SL; Hsu KC
    Phytomedicine; 2022 Jun; 100():154061. PubMed ID: 35364561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
    Bender O; Shoman ME; Ali TFS; Dogan R; Celik I; Mollica A; Hamed MIA; Aly OM; Alamri A; Alanazi J; Ahemad N; Gan SH; Malik JA; Anwar S; Atalay A; Beshr EAM
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200407. PubMed ID: 36403191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
    Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
    J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.